Literature DB >> 23218839

Suicide gene-mediated ablation of tumor-initiating mouse pluripotent stem cells.

Fei Chen1, Bing Cai, Yong Gao, Xiaofeng Yuan, Fuyi Cheng, Tao Wang, Meihua Jiang, Yijia Zhou, Bruce T Lahn, Weiqiang Li, Andy Peng Xiang.   

Abstract

Pluripotent stem cells, including embryonic stem (ES) and induced pluripotent stem (iPS) cells, serve as unlimited resources for cell replacement therapy and tissue engineering because such cells are capable of extensive proliferation in vitro and can give rise to lineages that represent any of the three embryonic germ layers. However, in the context of the in vivo behavior of cell transplants, key challenges need to be addressed and essential strategies should be developed before stem cells can be used in clinical practice. In the present study, we modified mouse ES/iPS cells to contain a suicide gene, deltaTK or CodA, under the transcriptional control of the EF1α or Nanog promoter. The suicide gene was introduced via lentivirus transduction without interfering with their self-renewal and pluripotency characteristics. We found that EF1α promoter-controlled deltaTK/CodA expression efficiently eliminated pluripotent stem cells and their derivatives both in vitro and in vivo. When the suicide gene was under the control of the Nanog promoter, tumor-initiating undifferentiated pluripotent stem cells were selectively ablated in vitro after prodrug treatment. These results indicate that modification of pluripotent stem cells with a suicide gene prior to transplantation offers a safe manner by which wayward stem cells, and their progeny, can be controlled in vivo. Our approach will render the clinical application of human pluripotent stem cells increasingly possible.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23218839     DOI: 10.1016/j.biomaterials.2012.11.018

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  20 in total

Review 1.  Preclinical studies for induced pluripotent stem cell-based therapeutics.

Authors:  John Harding; Oleg Mirochnitchenko
Journal:  J Biol Chem       Date:  2013-12-20       Impact factor: 5.157

2.  An Inducible Caspase-9 Suicide Gene to Improve the Safety of Therapy Using Human Induced Pluripotent Stem Cells.

Authors:  Shigeki Yagyu; Valentina Hoyos; Francesca Del Bufalo; Malcolm K Brenner
Journal:  Mol Ther       Date:  2015-05-29       Impact factor: 11.454

3.  Targeted Elimination of Tumorigenic Human Pluripotent Stem Cells Using Suicide-Inducing Virus-like Particles.

Authors:  Antonio Rampoldi; Stephen N Crooke; Marcela K Preininger; Rajneesh Jha; Joshua Maxwell; Lingmei Ding; Paul Spearman; M G Finn; Chunhui Xu
Journal:  ACS Chem Biol       Date:  2018-07-19       Impact factor: 5.100

Review 4.  Safeguarding clinical translation of pluripotent stem cells with suicide genes.

Authors:  Weiqiang Li; Andy Peng Xiang
Journal:  Organogenesis       Date:  2013-01-01       Impact factor: 2.500

Review 5.  Electroactive Scaffolds to Improve Neural Stem Cell Therapy for Spinal Cord Injury.

Authors:  Anthea R Mutepfa; John G Hardy; Christopher F Adams
Journal:  Front Med Technol       Date:  2022-02-22

6.  Development of an inducible caspase-9 safety switch for pluripotent stem cell-based therapies.

Authors:  Chuanfeng Wu; So Gun Hong; Thomas Winkler; David M Spencer; Alexander Jares; Brian Ichwan; Alina Nicolae; Vicky Guo; Andre Larochelle; Cynthia E Dunbar
Journal:  Mol Ther Methods Clin Dev       Date:  2014-11-12       Impact factor: 6.698

7.  Targeting of herpes simplex virus 1 thymidine kinase gene sequences into the OCT4 locus of human induced pluripotent stem cells.

Authors:  Wu Ou; Pingjuan Li; Jakob Reiser
Journal:  PLoS One       Date:  2013-11-29       Impact factor: 3.240

8.  Controlling immune rejection is a fail-safe system against potential tumorigenicity after human iPSC-derived neural stem cell transplantation.

Authors:  Go Itakura; Yoshiomi Kobayashi; Soraya Nishimura; Hiroki Iwai; Morito Takano; Akio Iwanami; Yoshiaki Toyama; Hideyuki Okano; Masaya Nakamura
Journal:  PLoS One       Date:  2015-02-23       Impact factor: 3.240

9.  'Above all, do no harm': safeguarding pluripotent stem cell therapy against iatrogenic tumorigenesis.

Authors:  Marek Malecki
Journal:  Stem Cell Res Ther       Date:  2014-06-03       Impact factor: 6.832

10.  A Safeguard System for Induced Pluripotent Stem Cell-Derived Rejuvenated T Cell Therapy.

Authors:  Miki Ando; Toshinobu Nishimura; Satoshi Yamazaki; Tomoyuki Yamaguchi; Ai Kawana-Tachikawa; Tomonari Hayama; Yusuke Nakauchi; Jun Ando; Yasunori Ota; Satoshi Takahashi; Ken Nishimura; Manami Ohtaka; Mahito Nakanishi; John J Miles; Scott R Burrows; Malcolm K Brenner; Hiromitsu Nakauchi
Journal:  Stem Cell Reports       Date:  2015-08-28       Impact factor: 7.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.